Q1 2021 PCI Biotech Holding ASA Earnings Call Transcript
Yes, good morning and welcome to PCI Biotech's Q1 Presentation held here at Oslo Cancer Cluster Innovation Park. My name is Ronny Skuggedal, and I'm the CFO of the company. Unfortunately, I need to inform you that our CEO, Per Walday, is acute ill, so I need to take this presentation on short notice. That's, of course, unfortunate, but I will do my best.
So before we start with the presentation, please notice our important notice and disclaimer. At the end of the presentation, we will have a Q&A session, open both through our telephone conference facility, where you can dial-in for questions; but you can also, as usual, post questions through the webcast console. We will start the Q&A sessions with the telephone conference facility. And you can find the details both in the slides and in the invite for the presentation.
So first, a couple of words, intro words about PCI Biotech. We have an enabling technology, enabling intracellular delivery. We use this platform technology for 3 different programs: fimaCHEM, our lead program, now in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |